At the news
? NEUTRALIMPACT 2/10 144 filed Nov 16, 2026 at 16:01 ET
CEO Emily M. Leproust filed a Form 144 notice of intent to sell 19,045 shares of Twist Bioscience common stock, valued at approximately $1.97 million, to cover a tax obligation from vested equity award settlement. The sale is routine and small relative to her prior trading activity and the company's market cap, carrying no material signal.
- Insider: CEO Emily M. Leproust
- Shares to be sold: 19,045 shares of common stock
- Approximate value: $1,974,745.58
- Sale date: November 16, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access